Tango Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Tango Therapeutics Inc in the second quarter 2026?
Tango Therapeutics Inc recorded a cumulative net loss of $-124 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -25.74%.

Within the Major Pharmaceutical Preparations industry 102 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2597 to 3139.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	659.17 %	134.78 %	73.51 %	-30.17 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-124	-107	-102	-101	-146
Return On Equity (TTM)	-25.74 %	-41.54 %	-50.3 %	-60.8 %	-79.72 %
TNGX's Total Ranking	# 3139	# 2597	# 2320	# 2971	# 2731
Equity (TTM) in Millions	1,025	392	346	160	135
Seq. Equity Change	161.69 %	13.09 %	116.32 %	18.58 %	-19.07 %
Seq. Net Income Change	-	-	-	-	-

Back to TNGX Management Effectiveness >> TNGX's 5 Years Annual ROE >> Compare TNGX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 103
Sector	# 296
Overall	# 3139

Return On Equity Statistics
High	Average	Low
-9.74 %	-42.59 %	-79.72 %
(Mar 31 2022)		(Jun 30 2025)

TNGX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	346	200	253	249	345
Y / Y Equity Change	73.51 %	-21.17 %	1.46 %	-27.64 %	793.13 %
Net Income in Millions	-102	-130	-102	-108	-58
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-29.35 %	-65.31 %	-40.2 %	-43.36 %	-16.89 %

Back to TNGX Management Effectiveness >> TNGX's 5 Years Annual ROE >> Compare TNGX ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TNGX's' Return on Equity at Yahoo Finance
TNGX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TNGX's Competitors
Subscribers only: Roe for Tango Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for TNGX's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-05T15:35:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.